You are here

Clinical Development

CRT's ultimate aim is to bring breakthrough therapeutics to cancer patients sooner. Our close working relationship with Cancer Research UK’s Centre for Drug Development (CDD) facilitates clinical development of novel therapeutic agents. To date, CDD has taken in excess of 140 agents into clinical trials, with five subsequently reaching the market.

Clinical Development Partnerships (CDP) is a joint initiative launched by Cancer Research Technology and Cancer Research UK. CDP aims to increase the number of successful new treatments for cancer patients by taking more novel agents or drugs into clinical development.

  • CENTRE FOR DRUG DEVELOPMENT

    Cancer Research UK’s Centre for Drug Development (CDD) is a centre of excellence in early phase cancer drug development, dedicated to pioneering new treatments to beat cancer sooner by working in partnership with the academic, pharmaceutical and biotechnology sectors. Its goal is to translate today’s science into tomorrow’s medicine.

    • Centre of excellence in early phase cancer drug development.
    • Provides expertise, facilities and connections between industry and academia necessary to translate today’s science into tomorrow’s medicine, by sponsoring, funding and managing pre-clincial and early clinical trials.
    • Focus: to develop new, cutting edge therapies that would not progress without CDD support.
    • Goal: to make more effective and kinder treatments available to people with cancer.
  • CLINICAL DEVELOPMENT PARTNERSHIPS

    Clinical Development Partnerships (CDP) is an innovative initiative launched by the Cancer Research UK Centre for Drug Development and CRT to release the untapped potential in oncology drug development.

    The scheme is primarily targeted at leading pharmaceutical and biotechnology companies who require resource, capabilities or expertise to develop new agents for the treatment of cancer.

    Read more about CDP

CENTRE FOR DRUG DEVELOPMENT Open

Cancer Research UK’s Centre for Drug Development (CDD) is a centre of excellence in early phase cancer drug development, dedicated to pioneering new treatments to beat cancer sooner by working in partnership with the academic, pharmaceutical and biotechnology sectors. Its goal is to translate today’s science into tomorrow’s medicine.

  • Centre of excellence in early phase cancer drug development.
  • Provides expertise, facilities and connections between industry and academia necessary to translate today’s science into tomorrow’s medicine, by sponsoring, funding and managing pre-clincial and early clinical trials.
  • Focus: to develop new, cutting edge therapies that would not progress without CDD support.
  • Goal: to make more effective and kinder treatments available to people with cancer.

Related links

CLINICAL DEVELOPMENT PARTNERSHIPS Open

Clinical Development Partnerships (CDP) is an innovative initiative launched by the Cancer Research UK Centre for Drug Development and CRT to release the untapped potential in oncology drug development.

The scheme is primarily targeted at leading pharmaceutical and biotechnology companies who require resource, capabilities or expertise to develop new agents for the treatment of cancer.

Read more about CDP

Related links